Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.

Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA7 May 2022Cited by 35 (Europe PMC)

PMID35524068PMCIDPMC9499892DOI10.1007/s00198-022-06413-yPepBankPUB-35524068

Read at source PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In matched women with osteoporosis, abaloparatide was associated with similar nonvertebral fracture incidence to teriparatide.
In plain wordsIn women with osteoporosis, abaloparatide was linked to similar nonvertebral fracture incidence compared with teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeNonvertebral fracture incidence
Study
n = 23,232
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Nonvertebral fracture hazard ratio
0.89 ratio
abaloparatide versus teriparatide
Nonvertebral fracture hazard ratio 95% CI
0.77 to 1.03 ratio
abaloparatide versus teriparatide
Patients with nonvertebral fracture
335 patients
abaloparatide, over 19 months
Patients with nonvertebral fracture
375 patients
teriparatide, over 19 months
Source sentences
Summary
Over 19 months, 335 patients on abaloparatide and 375 on teriparatide had a NVF (hazard ratio [95% confidence interval]: 0.89 [0.77, 1.03]), and 121 and 154 patients, respectively, had a hip fracture [HR (95% CI): 0.78 (0.62, 1.00)].
3 context sentences(design, population, supporting numbers)
Summary · context
Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy.
Summary · context
In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.
Summary · context
Propensity score matching yielded 11,616 patients per cohort.
Report a problemFND-3552406801
02HumanObservational studyEfficacy outcome
In matched women with osteoporosis, teriparatide was associated with similar nonvertebral fracture incidence to abaloparatide.
In plain wordsIn women with osteoporosis, teriparatide was linked to similar nonvertebral fracture incidence compared with abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNonvertebral fracture incidence
Study
n = 23,232
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Nonvertebral fracture hazard ratio
0.89 ratio
abaloparatide versus teriparatide
Nonvertebral fracture hazard ratio 95% CI
0.77 to 1.03 ratio
abaloparatide versus teriparatide
Patients with nonvertebral fracture
335 patients
abaloparatide, over 19 months
Patients with nonvertebral fracture
375 patients
teriparatide, over 19 months
Source sentences
Summary
Over 19 months, 335 patients on abaloparatide and 375 on teriparatide had a NVF (hazard ratio [95% confidence interval]: 0.89 [0.77, 1.03]), and 121 and 154 patients, respectively, had a hip fracture [HR (95% CI): 0.78 (0.62, 1.00)].
3 context sentences(design, population, supporting numbers)
Summary · context
Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy.
Summary · context
In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.
Summary · context
Propensity score matching yielded 11,616 patients per cohort.
Report a problemFND-3552406802
03HumanObservational studyEfficacy outcome
In matched women with osteoporosis, abaloparatide was associated with lower hip fracture incidence than teriparatide.
In plain wordsIn women with osteoporosis, abaloparatide was linked to fewer hip fractures than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseHip fracture incidence
Study
n = 23,232
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Hip fracture hazard ratio
0.78 ratio
abaloparatide versus teriparatide
Hip fracture hazard ratio 95% CI
0.62 to 1 ratio
abaloparatide versus teriparatide
Patients with hip fracture
121 patients
abaloparatide, over 19 months
Patients with hip fracture
154 patients
teriparatide, over 19 months
Source sentences
Summary
Over 19 months, 335 patients on abaloparatide and 375 on teriparatide had a NVF (hazard ratio [95% confidence interval]: 0.89 [0.77, 1.03]), and 121 and 154 patients, respectively, had a hip fracture [HR (95% CI): 0.78 (0.62, 1.00)].
3 context sentences(design, population, supporting numbers)
Summary · context
Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy.
Summary · context
In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.
Summary · context
Propensity score matching yielded 11,616 patients per cohort.
Report a problemFND-3552406803
04HumanObservational studyEfficacy outcome
In matched women with osteoporosis, teriparatide was associated with higher hip fracture incidence than abaloparatide.
In plain wordsIn women with osteoporosis, teriparatide was linked to more hip fractures than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHip fracture incidence
Study
n = 23,232
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Hip fracture hazard ratio
0.78 ratio
abaloparatide versus teriparatide
Hip fracture hazard ratio 95% CI
0.62 to 1 ratio
abaloparatide versus teriparatide
Patients with hip fracture
121 patients
abaloparatide, over 19 months
Patients with hip fracture
154 patients
teriparatide, over 19 months
Source sentences
Summary
Over 19 months, 335 patients on abaloparatide and 375 on teriparatide had a NVF (hazard ratio [95% confidence interval]: 0.89 [0.77, 1.03]), and 121 and 154 patients, respectively, had a hip fracture [HR (95% CI): 0.78 (0.62, 1.00)].
3 context sentences(design, population, supporting numbers)
Summary · context
Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy.
Summary · context
In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.
Summary · context
Propensity score matching yielded 11,616 patients per cohort.
Report a problemFND-3552406804
05HumanObservational studySafety outcome
In matched women with osteoporosis, major adverse cardiovascular event rates were similar with abaloparatide and teriparatide.
In plain wordsIn women with osteoporosis, abaloparatide was linked to similar major cardiovascular event rates compared with teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeMajor adverse cardiovascular events
Study
n = 23,232
Comparator
Teriparatide
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The MACE and MACE + HF rates were similar between cohorts.
3 context sentences(design, population, supporting numbers)
Summary · context
Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy.
Summary · context
In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.
Summary · context
Propensity score matching yielded 11,616 patients per cohort.
Report a problemFND-3552406805
06HumanObservational studySafety outcome
In matched women with osteoporosis, major adverse cardiovascular event rates were similar with teriparatide and abaloparatide.
In plain wordsIn women with osteoporosis, teriparatide was linked to similar major cardiovascular event rates compared with abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMajor adverse cardiovascular events
Study
n = 23,232
Comparator
Abaloparatide
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The MACE and MACE + HF rates were similar between cohorts.
3 context sentences(design, population, supporting numbers)
Summary · context
Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy.
Summary · context
In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.
Summary · context
Propensity score matching yielded 11,616 patients per cohort.
Report a problemFND-3552406806
07HumanObservational studySafety outcome
In matched women with osteoporosis, MACE and MACE plus heart failure rates were similar with abaloparatide and teriparatide.
In plain wordsIn women with osteoporosis, abaloparatide was linked to similar rates of major cardiovascular events, with or without heart failure, compared with teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeMACE and MACE plus heart failure rates
Study
n = 23,232
Comparator
Teriparatide
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The MACE and MACE + HF rates were similar between cohorts.
3 context sentences(design, population, supporting numbers)
Summary · context
Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy.
Summary · context
In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.
Summary · context
Propensity score matching yielded 11,616 patients per cohort.
Report a problemFND-3552406807
08HumanObservational studySafety outcome
In matched women with osteoporosis, MACE and MACE plus heart failure rates were similar with teriparatide and abaloparatide.
In plain wordsIn women with osteoporosis, teriparatide was linked to similar rates of major cardiovascular events, with or without heart failure, compared with abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMACE and MACE plus heart failure rates
Study
n = 23,232
Comparator
Abaloparatide
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
The MACE and MACE + HF rates were similar between cohorts.
3 context sentences(design, population, supporting numbers)
Summary · context
Anonymized US patient claims data from Symphony Health, Integrated Dataverse (IDV)®, May 1, 2017 to July 31, 2019, included women aged ≥ 50 years with ≥ 1 prescription of abaloparatide or teriparatide and no prior anabolic therapy.
Summary · context
In 1:1 propensity score matched cohorts, time to first NVF following index date, major adverse cardiovascular events (MACE), and MACE + heart failure (HF) were compared between cohorts using a Cox proportional hazards model.
Summary · context
Propensity score matching yielded 11,616 patients per cohort.
Report a problemFND-3552406808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedResults postedNCT04974723

Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Radius Health, Inc.n = 22,0541 Jul 2021 to 30 Sept 2021

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 19 Apr 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.